People

Name Mertlíková-Kaiserová Helena
Position Head of the Research-Service Group
Dr. Helena Mertlíková-Kaiserová

Helena Mertlíková-Kaiserová, Ph.D.

Head of the Team


Biochemical Pharmacology of Antimetabolites
Institute of Organic Chemistry and Biochemistry ASCR, v.v.i.
Flemingovo nám. 2, CZ-166 10 Prague 6, Czech Republic

☎: (+420) 220 183 114

 
Education
2003-2007 Ph.D. in Biochemistry, under supervision of Prof. Dr. E. Kvasnièková (field: Pathobiochemistry and Xenobiochemistry), Faculty of Pharmacy in Hradec Králové, Charles University in Prague.
1998-2003 M.Sc. in Pharmacy, under supervision of Prof. Dr. E. Kvasnièková, Faculty of Pharmacy in Hradec Králové, Charles University in Prague.
 
Experience
2005 Internship at the Department of Pharmacology and Toxicology, University of Maastricht - Prof. Dr. A.Bast.
 
Appointments
since 2010 Head of the "Biochemical Pharmacology of Antimetabolites" research-service team, Institute of Organic Chemistry and Biochemistry, v.v.i., AS CR, Prague.
2009-2010 Scientist at Prof. Dr. A. Holý research team, Institute of Organic Chemistry and Biochemistry v.v.i., AS CR, Prague.
2007-2009 Postdoctoral fellow with Prof. Dr. A. Holý, Institute of Organic Chemistry and Biochemistry v.v.i., AS CR, Prague.
 
Awards and Fellowhisps
2009 Medal of the Faculty of Pharmacy, Charles University (at the occasion of 40th anniversary of the faculty's foundation).
2007 Prize of the Czech Minister of Education for excellent results and creativity during the postgraduate studies in the field of Pathobiochemistry and Xenobiochemistry.
2003 Dean's Prize for the graduate students with excellent results during their studies (Charles University, Faculty of Pharmacy).
2002 Czech Pharmaceutical Society's Prize for best student's research work: lecture "Contribution to the preclinical evaluation of new lipophilic iron chelators" presented at Student's Scientific Conference in Hradec Králové, April 2002.
 
Research interest
Biochemistry and biochemical pharmacology of nucleoside/nucleotide analogs, anticancer drugs, apoptosis, DNA damage, reactive oxygen species.
 
Papers
14 papers in journals with IF (cumulative IF - 40.8)